September 25, 2015Open Access

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Toni K. Choueiri

Bernard Escudier

Thomas Powles

Journals

New England Journal of Medicine

Actions

Institutions

University College London

Washington University in St. Louis

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study